Introduction
chondrial fatty acid metabolism may cause cardiomyopathy and arrhythmias that can lead to cardiac Despite the abundant literature dealing with the metabofailure. lism of fatty acid in the heart, there is a limited understanding (and to the best of our knowledge no comprehensive
In this review, we discuss the information available review) concerning the role that cardiac lipid and fatty acid concerning the molecular and cellular basis of fatty acid metabolism plays in the genesis and progression of cardiac and lipid metabolic perturbations which can lead to cardiac failure.
failure. In this context, we will focus on the molecular and What is presently known is:
biochemical players as well as the events that occur in both the genetic abnormalities in fatty acid metabolism that lead (a) Fatty acids and associated lipids play an important role to cardiomyopathy and cardiac failure, as well as in cardiac in cardiomyocytes structure and function. There is hypertrophy and apoptosis. The term cardiac failure is considerable evidence that in the post-natal and adult broadly used as a pathophysiologic state where the heart is mammalian heart, fatty acid b oxidation is the preunable to meet the metabolic requirements of the body. ferred pathway for the energy that is required for Most of this review is directed to our understanding of the efficient cardiac pumping.
mechanisms, diagnosis and treatment of fatty acid defects (b) Specific defects (either inherited or acquired) in mitooccurring in human cardiac failure. Experimental findings of defects in fatty acid metabolism are also discussed with respect to current and future use of animal models.
Since the literature is abundant (including numerous
Abbreviations: ACC, acetyl coA carboxylase; ATP, adenosine trireviews) on the subject of acquired and inherited lipid phosphate; CPT, carnitine palmitoyl transferase; DCM, dilated cardisorders in the development of coronary artery disease diomyopathy; ETF, electron-transfer flavoprotein; FADH2, flavin adenine and stroke (e.g., cholesterol, the apolipoproteins and HDL / dinucleotide (reduced form); FABP, fatty acid binding protein; FAT, fatty LDL), we have omitted these subjects from our review.
acid translocase; FATP, fatty acid transport protein; HADHA, human mitochondrial trifunctional protein subunit A; HADHB, human mitochondrial trifunctional protein subunit B; HCM, hypertrophic cardiomyopathy; LCAD, long-chain acyl-CoA dehydrogenase; LCHAD, structural and functional nature of the cardiac plasma and A key regulatory event in the uptake of fatty acids into mitochondrial membranes. Their influence on the fluidity myocardial mitochondria involves changes in the levels of and stability of membrane structure markedly impacts on the metabolite malonyl CoA which functions as a potent membrane functions such as transport of the ions and allosteric inhibitor of CPT-I. Malonyl CoA is synthesized substrates, and the electrophysiology which is intrinsic to by the enzyme acetyl coA carboxylase (ACC) from cardiac function and cardiac excitability. In addition to the cytoplasmic acetyl CoA. Levels of malonyl CoA are structural and functional roles played within the cardiac altered by changed levels of the acetyl CoA or by membrane, fatty acids and associated lipids are also modulation of the ACC activity. Levels of the cytoplasmic recognized as regulatory molecules with roles in cell acetyl CoA increase either as a function of decreased TCA signaling, second messengers in transduction, as effectors cycle activity reflecting lowered metabolic demand or as a in apoptosis (cell death) and in responses to oxidative and result of increased pyruvate dehydrogenase activity. Thereischemic damage.
Role of fatty acids and their metabolism in the
fore malonyl CoA production linked to altered metabolic demand or utilization of carbohydrate resources can in turn 2.2. Transporters and carriers impact on either the down or up-regulation of fatty acid import into mitochondria and myocardial fatty acid oxidaEntry of fatty acids into the myocardial cell while not tion. ACC activity is allosterically regulated by citrate and fully delineated is presently thought to be mediated by by kinase-mediated phosphorylation. several proteins including fatty acid binding proteins (FABPs) and a myocardial-specific integral membrane transporter (fatty acid translocase or FAT). The non-en-2.3. Bioenergetics of fatty acid oxidation zymatic FABP also serves as a facilitator of intracellular transport of relatively insoluble long-chain fatty acids to
The mitochondrial fatty acid b oxidation pathway sites of metabolic utilization (e.g., mitochondria). In mamcontains four reaction steps including acyl-CoA dehydromals, the FABP content in skeletal and cardiac muscle is genases (short-chain, SCAD, medium-chain, MCAD, longrelated to the fatty acid oxidation capacity of the tissue [1] .
chain, LCAD and very-long-chain, VLCAD), short-chain Prior to transport into the mitochondria, fatty acids must enoyl-CoA hydratase, b-hydroxyacyl CoA dehydrogenase be activated in the cytoplasm. The net result of this and b-ketoacyl CoA thiolase as shown in Fig. 2 . activation process is the consumption of ATP, and requires
In the initial acyl-CoA dehydrogenase reaction, VLCAD CoA-SH. Activation is catalyzed by fatty acyl-CoA and LCAD are responsible for the enzymatic dehydrogenasynthetases (at least three different acyl-CoA synthetase tion of long-chain C8-C22 fatty acids (e.g., palmitate and enzymes have been described whose specificities depend linoleic acids) with VLCAD having greater activity with on fatty acid chain length) associated with either the the longer-chain substrates (e.g., C22 and C24 acyl-CoA endoplasmic reticulum or the outer membrane of the esters), MCAD is active with the C4-C12 straight-chain mitochondria.
fatty acids (e.g., decanoic acid) and SCAD primarily is For the b oxidation pathway to function, the fatty active with C2-C4 fatty acids (e.g., butyryl coA). acyl-CoA has to be transported across the inner mito-
The remaining enzymatic reactions of b oxidation are chondrial membrane. Long-chain fatty acyl-CoA moleperformed by a highly organized single enzymatic complex cules cannot pass directly across the inner mitochondrial known as the mitochondrial trifunctional protein (MTP) membrane and need to be transported as carnitine esters associated with the mitochondrial inner membrane. Recent whereas short-chain and medium-chain fatty acids can be studies have indicated that an entirely different set of easily transported without the assistance of carnitine.The enzymes responsible for the b oxidation of medium and transport of long-chain fatty acyl-CoA into the mitochonshort-chain fatty acids is present in the mitochondrial dria depicted in Fig. 1 is accomplished via an acylmatrix [2, 3] . carnitine intermediate, which itself is generated by the The process of fatty acid oxidation is termed b oxidation action of carnitine palmitoyltransferase I (CPT-I), an since it occurs through the sequential removal of 2-carbon enzyme residing in the inner face of the outer mitounits by oxidation at the b-carbon position of the fatty chondrial membrane. catalyzes the regeneration of the fatty acyl-CoA molecule, acetyl-CoA oxidation in the TCA cycle will subsequently with the acyl group transferred back to CoA from carenter the respiratory pathway for the production of ATP. nitine. Once inside the mitochondrion the fatty acid-CoA is Consequently, the oxidation of fatty acids yields more a substrate for the b oxidation machinery.
energy per carbon atom than does the oxidation of carbohydrates. However, while fatty acids produce more 2.4. Cellular location ATP during complete aerobic oxidation than glucose, this occurs at the expense of a higher rate of oxygen consumpBoth peroxisomes and mitochondria have multiple ention. The supply of oxygen can be an important deterzymes involved in fatty acid b oxidation. neonatal adrenoleukodystrophy where there is little or no The inducible enzymes increase in response to the peroxcardiac involvement. Recent evidence (discussed below) isomal proliferating activating receptor (PPAR) resulting in demonstrates a pivotal role of the PPAR regulation in both increased peroxisomal biogenesis (see below). mitochondrial fatty acid oxidation and mitochondrial bioIt is important to note that while specific deficiencies in genesis, not only in normal cardiac growth and developthe mitochondrial-located enzymes involved in fatty acid b ment but also in cardiac failure. This suggests an important oxidation may result in cardiomyopathy (as discussed more inter-relationship between the two cellular compartments fully below), defects in the peroxisomal fatty acid b and further underscores the mitochondrial compartment as oxidation enzymes primarily result in neurological complia critical effector of cardiac homeostasis. The commonality cations including seizures, hypotonia and psychomotor of biogenesis and potential feedback between these two cellular organelles needs further elucidation in both normal This is supported by data demonstrating the co-occurrence growth and development and in cardiac disease (both fatty of these proteins in muscle and their co-ordinate regulation acid and mitochondrial OXPHOS disorders).
during development in both cardiac and muscle tissue [9] . Transcripts for the integral membrane fatty acid transport protein (FATP), fatty acid translocase (FAT), the plasma 3. Changes occur in fatty acid regulation during membrane-associated fatty acid-binding protein (FABPpm) cardiac growth and development and the cytoplasmic heart-type fatty acid-binding protein (H-FABPc) showed high expression levels in heart, some-3.
Fetal to post-natal transition
what lower in red skeletal muscle and significantly lower in white skeletal muscle. However, FATP, FAT and HIn the fetal heart which functions in a relatively hypoxic FABPc displayed three-to fivefold increases in mRNA environment, glucose and lactate are the predominant fuel expression during cardiac growth, while the FABPpm substrates utilized by glycolysis and lactate oxidation, expression remained relatively constant [9] . respectively. Postnatally, a switch occurs so that fatty acids become the chief energy substrate thereafter in the adult 3.3. Aging and senescence mammalian heart [4] . Genes encoding the fatty acid enzymes are expressed at low levels in the fetal and Many changes have been noted in cardiac muscle with neonatal rat heart and are significantly and coordinately advancing age related to modifications in membrane fatty upregulated ($70%) in adult rat hearts compared to the acid composition, decreasing levels of polyunsaturated fetal expression patterns. This switch operates at both fatty acids and increasing levels of saturated fatty acids. transcriptional and post-transcriptional levels [4] . For Several studies have also reported significant reduction in example, MCAD mRNA levels in rats increased 2-3-fold heart mitochondrial cardiolipin content with aging [10, 11] . at birth followed by a decline during the first postnatal
The unique anionic phospholipid cardiolipin is the princiweek in heart and liver. The pattern of accumulation of ple polyglycerophospholipid (carrying four acyl groups and MCAD mRNAs in rat heart during the weaning and early two negative charges) found in the heart, the most unsatuadult periods was similar [5] .
rated cellular phospholipid and localizes predominantly in mitochondria. The age-related reduction in cardiolipin is 3.2. Post-natal to adult considered to have major impact on cardiac mitochondrial membrane transport function, fluidity and stability. Studies The expression patterns of mitochondrial carnitine palwith cultured adult cardiomyocytes isolated from rat hearts mitoyltransferase (CPT) enzymes examined in the deof broad age range also exhibited changes in the fatty acid veloping rat heart show a marked change during this profile related to alterations in the mechanism of desaturaperiod. The specific activity of CPT-II increases approxition and elongation of essential fatty acids. The ability of mately threefold during the first month of life as does heart cells to metabolize linoleic acid to higher and more myocardial carnitine levels. Two kinetically different unsaturated metabolites decreased with age. With aging, tissue-specific isoforms of CPT-I, CPT-I a and CPT-I b, the pattern of fatty acids of the cultured cardiomyocytes have been identified which are immunologically distinct showed a gradual but significant shift, similar to that proteins [6] . The CPT-I a or L form is expressed in highest reported in the whole heart [12] . abundance in the liver, pancreas and heart; the b gene or Presently, data on cardiac carnitine levels in healthy M form is expressed predominantly in skeletal muscle, aging people is sparse. However, a marked reduction of adipose tissue, heart and testis. Cardiac ventricular carnitine and its derivatives in muscle, and of long-chain myocytes are the only cells known to express both CPT-I acylcarnitine has been reported in hearts of older mice and isoforms. Developmentally, expression of CPT-I a gene is rats, when compared to younger animals. Analysis of very high in the fetal heart and declines following birth. muscle samples of healthy humans showed drastic reduc-CPT-I b, is also highly expressed in fetal myocytes and tion of carnitine and acetyl carnitine in older subjects with remains so throughout development. Therefore, in the adult strong reverse correlation between age and carnitine levels heart CPT-I a represents a very minor constituent, while [13, 14] . its contribution is much greater in the newborn. CPT-I a is also subject to hormonal regulation, increasing during fasting and diabetes, and decreasing upon weaning with a 4. Disorders of fatty acid metabolism affect cardiac high carbohydrate diet; CPT-I b gene is not subject to the structure / function same developmental or hormonal controls imposed on CPT-I a [6, 7] .
In cardiac failure following cardiac hypertrophy, there is As previously noted, specific membrane-associated and a major switch in myocardial bioenergetic substrate used, cytoplasmic proteins are involved in the uptake of longfrom fatty acid to glucose. A key component and marker of chain fatty acids by cardiac and skeletal muscle cells [8] .
the switch is the co-ordinate down-regulation of fatty acid b oxidation enzymes and mRNA levels (.40%) in the pate in carnitine transport and metabolism may cause human left ventricle [15] . dilated cardiomyopathy as a recessive trait [22, 23] . This switch is thought to represent a reversal to a fetal One of the loci effected in carnitine-associated cardiac energy substrate preference pattern in the heart. During the involvement includes the plasma-membrane localized cardevelopment of cardiac hypertrophy, a fetal metabolic rier which transports carnitine into the cell; its deficiency gene program is initiated via the complicity of transcriphas been described as primary carnitine deficiency [24] . tion factors which bind to regulatory elements reducing This transport deficiency is due to specific defects in the fatty acid oxidation gene expression (e.g., MCAD and gene (OCTN2) encoding the plasma-membrane localized CPT-I b). Although the molecular mechanism(s) mediating organic cation / carnitine transporter [25] . Defects in a this down-regulation is not fully understood, the participasecond locus, the mitochondrial membrane localized cartion of several nuclear receptors, intermediate metabolites nitine translocase also lead to carnitine deficiency resulting and transcription factors (e.g., SP1 and PPAR) has been in cardiomyopathy and cardiac failure [26] . implicated in this programmatic change in gene expression Although generally not found associated with car-(see further discussion in Section 5) [16] .
diomyopathy / cardiac failure, new evidence suggests that CPT-I deficiency can result in cardiac involvement [27] . In contrast, there is general consensus that deficiencies in 4.1. Specific heritable (inborn) deficiencies in fatty acid CPT-II (specifically infantile CPT-II deficiency), an aumetabolism are associated with cardiomyopathy and tosomal recessive disorder, is associated with cardiac cardiac failure damage and sudden death [28] . The utilization of fatty acids as an energy source failure [17] . In general, defects in the oxidation of longrequires the functional operation of the mitochondrial chain fatty acids are more likely to cause cardiomyopathy electron chain and OXPHOS; the NADH feeds into the than defects in medium-chain or short-chain fatty acids.
electron transport chain at complex I and electrons are Specific defects in enzymes involved in long-chain and transferred from acyl CoA dehydrogenases via the elecvery long-fatty-acid-chains have been identified [18] [19] [20] tron-transfer flavoprotein (ETF), ETF dehydrogenase and and the genetic defects will be described further in the ubiquinone (or coenzyme Q) to complex III as depicted in molecular section below. Moreover, although severe car- Fig. 2 [29] . Affected individuals with deficiencies in the diomyopathy is unusual in patients with MCAD de-ETF pathway display impaired fatty acid oxidation and ficiency, sudden death in children is a common outcome, abnormal intra-mitochondrial accumulation of fatty acids and its pathogenetic mechanism is presently undetermined.
and glutaric acid and may develop a fatal cardiomyopathy Similarly, a recent study indicates that cardiomyopathy can [29, 30] . Similarly, patients with defects in respiratory be part of the clinical phenotype of SCAD deficiency [21] .
complexes (e.g., complexes I and IV) will frequently Carnitine deficiency has been frequently associated with develop cardiomyopathy and cardiac failure largely as a severe cardiomyopathy. Mutations in proteins that particiresult of impaired energy production [31] However, the extent of the effects on the cardiac fatty acid b oxidation and on lipid accumulation in patients with defined respiratory activity defects and with defective coenzyme Q levels Table 1 has not yet been fully assessed.
Fatty acid metabolism disorders in cardiac failure
Fatty acid metabolism disorders Affected loci Ref.
Fatty acid metabolism defects can be associated
CPT-II deficiency ICV [26, 52, 53] with either HCM or DCM long-chain L-3 hydroxylacyl-CoA activity and are associ-VLCAD deficiency VLCAD [18, 51] ated with DCM [32] , most of the disturbances in fatty acid CPT-I deficiency L-CPT-I [25, 78] metabolism are found in patients with hypertrophic carCarnitine transport OCTN2 [22, 23] diomyopathy (HCM) and many of the reported mutations Carnitine translocase deficiency CAC [26] in fatty acid b oxidation pathway result in HCM rather
MCAD deficiency MCAD [48-50] ETF deficiency
ETFa [29] than dilated cardiomyopathy (DCM) [33] .
ETF dehydrogenase deficiency ETFdH [30] Barth syndrome, an X-linked disorder, is characterized
by a triad of dilated cardiomyopathy, neutropenia and increased levels of 3-methylglutaconic aciduria with onset membrane(s) may prove to be of great significance in the often occurring in infancy. Arrhythmias and heart failure development of new therapies. are frequently present. The protein tafazzin (encoded by ]] the G4.5 gene) is mutated and responsible for Barth syndrome with associated cardiomyopathy [34, 35] . While 4.5. Fatty acids and cardiac apoptosis the biochemical function of the tafazzin protein has not yet been determined, structural analysis suggests that tafazzin Apoptosis (programmed cell death) plays a prominent belongs to a family of acyltransferases involved in phosrole in the myocyte loss that occurs in human cardiac pholipid synthesis [36] .
failure [42, 43] . It also plays a major role in the extensive A recent report reveals that the levels of cardiolipin are cardiac remodeling that encompasses the transition from markedly reduced in cultured fibroblasts from patients with cardiac hypertrophy to heart failure (in models such as the the G4.5 mutation. This may be the first report of a human spontaneously hypertensive rat) [44] . disorder with a defect in cardiolipin metabolism [37] , and
One of the hallmarks of apoptosis and an early regulait may prove to be useful to assess the cardiac levels of tory event is the release of cytochrome c from mitocardiolipin in patients with Barth syndrome.
chondria into the cytosol. The release of cytochrome c has been shown to be necessary for the activation of a cascade 4.4. Abnormalities in fatty acid oxidation lead to of downstream cysteine-aspartate proteases (caspases) and cardiac arrhythmias and conduction defects nuclear endonucleases. The mechanism of cytochrome c release from the inner mitochondrial membrane has not Conduction defects and cardiac arrhythmias have been been fully elucidated. In addition, mitochondrial membrane shown to be frequently present in patients with certain permeabilization is a critical early step of apoptosis defects in fatty acid oxidation [38] . Specifically, these preceding the caspase cascade. The permeabilization is cardiac defects were present in patients with deficiencies in accompanied by an early dissipation of the mitochondrial CPT-II deficiency, carnitine translocase and MTP detransmembrane potential [45] . Opening the mitochondrial ficiency. Cardiac arrhythmias were notably absent in permeability transition pore is accompanied by the depopatients with: deficiencies in CPT-I, the primary carnitine larization of the mitochondrial membrane. A component of carrier and MCAD.
the inner membrane which is associated with the mitoThese findings strongly suggest that the accumulation of chondrial pore as well as with cytochrome c is the arrhythmogenic intermediary metabolites of fatty acids phospholipid cardiolipin. Cardiolipin also mediates the (e.g., long-chain acylcarnitines) may be responsible for targeting of the pro-apoptotic protein, tBid to mitochondria arrhythmias and potentially contributory to cardiac failure implicating cardiolipin in the pathway for cytochrome c and sudden death. This is consistent with the findings that release [46] . It is also thought to play a role in membrane long-chain acylcarnitines accumulate with the defects in permeability and proton conductance as well as func-CPT-II, carnitine translocase and MPT whereas MCAD, tioning of cytochrome c oxidase. CPT-I and carnitine carrier do not result in accumulation During ischemia, oxidation of the saturated fatty acid of these intermediates.
palmitate is associated with diminished myocyte function Amphiphilic long-chain acylcarnitines have detergent- [47] . Saturated long-chain fatty acid substrates such as like properties, can extensively modify membrane proteins palmitate (but not mono-unsaturated fatty acids) readily and lipids, and have a variety of toxic effects on the induce apoptosis in rat neonatal cardiomyocytes [48, 49] . electrophysiological function of cardiac membranes includAs an early feature of palmitate-induced cardiomyocyte 1 21 ing ion transport (Na , Ca ), and impaired gap junction apoptosis, palmitate diminishes the content of the mitoactivity. This is further supported by the demonstration chondrial cardiolipin by causing a marked reduction of that patients with cardiomyopathy due to inborn defects in cardiolipin synthesis. Decreased levels of cardiolipin syncarnitine translocase have an increased onset of cardiac thesis and cytochrome c release have been recently rearrhythmias [39] . Moreover, the accumulation of longported to be directly temporally correlated. This suggests chain fatty acid intermediates (e.g., acylcarnitine) has been that cardiolipin modulates the association of cytochrome c implicated in the genesis of ventricular rhythm disorders with the mitochondrial inner membrane [50] . during myocardial ischemia [40] . Selective blocking of Palmitate also decreases the oxidative metabolism of CPT-I activity prevents the accumulation of potentially fatty acids and causes increases in the intracellular second toxic long-chain esters during hypoxia / ischemia, thereby messenger ceramide [47] paralleling a decrease in complex reducing the risk of electrophysiologic disturbance and III activity. The decrease in fatty acid metabolism (e.g., membrane disruption [41] .
CPT-I activity declines) and complex III activities and Studies to define the precise site of action of these toxic ceramide accumulation have been shown to be downstream long-chain intermediates within the cardiomyocytes e.g., at events occurring well after cytochrome c release (and the level of the plasma membrane, mitochondrial matrix or changes in the permeability transition pore) [49] [50] [51] .
Molecular players and events in fatty acid related 5.4. MTP cardiac diseases; genes and modulation of gene expression
MTP, an enzyme of b oxidation of long-chain fatty acids, is a multienzyme complex composed of four mole-5.1. MCAD cules of the a-subunit (encoded by HADHA) which contains both the enoyl-CoA hydratase and 3-hydroxyacyl-MCAD deficiency is autosomally recessive and associCoA dehydrogenase domains, and four molecules of the ated with sudden death. Over 90% of cases of MCAD b-subunit (encoded by HADHB) containing the 3-deficiency are associated with a homozygous mutation at ketoacyl-CoA thiolase domain [58] . base pair (bp) 985 (A985G). This mutation directs a MTP deficiency is classified into two different bioglutamate replacement of lysine at residue 304 in the chemical phenotypes: (1) both a and b subunits are mature MCAD subunit causing impairment of tetramer present and only the 3-hydroxyacyl-CoA dehydrogenase assembly and increased protein instability [52] . MCAD (LCHAD) activity is effected; (2) the absence of both deficiency is the most frequent inborn metabolic disorder subunits, and the complete lack of all three enzymatic in populations of Northwestern European origin [53] .
activities of MTP. Although there is some overlap between At the gene level, three of the seven reported non the clinical features found in each molecular / biochemical A985G mutations found in MCAD deficiency localize to phenotype, patients with neonatal cardiomyopathy have the exon 11. At the protein level, the mutant residues cluster in second biochemical phenotype only. The most common helix H of the MCAD protein and are proposed to have mutation associated with MTP deficiency (G1528C) is their primary effect on the correct folding and assembly of associated with the first phenotype and not with the the tetrameric MCAD enzyme structure. The amino acid second. Mutations have been localized to the 59 donor residues effected are: M301T, S311R and K304E [54] .
splicing site of the a subunit gene which can result in the entire loss of an exon in the mRNA (exon 3) [32] and are associated with the second phenotype. Both DNA and 5.2. VLCAD enzymatic testing can be performed in fetal screening of this often devastating disease [59] . Pediatric cardiomyopathy is the most common clinical phenotype of VLCAD deficiency. A severe form of 5.5. PPAR infantile cardiomyopathy is found in over 67% of cases, often resulting in sudden death [20] . VLCAD deficiency is A family of nuclear gene receptors, peroxisomal prolifcharacterized by a marked reduction of VLCAD mRNA erating activating receptors (PPARs) has been identified as and decreased levels and / or absence of VLCAD enzyme playing a key role in the transcriptional regulation of genes activity. Mutation analysis of the VLCAD gene revealed a involved in intra-cellular lipid and energy metabolism large number of different mutant loci (21 in 19 patients) including fatty acid oxidation enzymes [60] . These rewith few repeated mutations [55] . Distinguishing between ceptors are enriched in tissues that are dependent on lipid truly pathogenic mutations and polymorphic variations utilization for energy metabolism (e.g., heart, liver, brown remains to be done.
adipose tissue) playing a major role in the rapid mobilization of bioenergetic stores in response to physiological 5.3. CPT-II stresses. PPAR is a transcription factor which activates expresThe infantile form of CPT-II deficiency has frequent sion of a constellation of genes encoding enzymes incardiac involvement and is associated with specific CPT-II volved in both peroxisome and mitochondrial fatty acid mutations. This is in contrast to the adult form of CPT-II oxidation (e.g., mitochondrial MCAD, CPT-I and peroxdeficiency which does not present with cardiac inisomal acyl CoA oxidase). PPAR activity is dependent on volvement; hence mutations involved in the adult CPT-II the presence of a variety of activating ligands (e.g., phenotype (although residing within the same gene) are not prostaglandins, eicosanoids, long-chain unsaturated fatty further discussed in this review.
acids, etc.) and interacting proteins (i.e., co-activators and The infantile CPT-II deficiency has been associated with co-repressors). Activated PPAR-ligand complex binds to a several mutations including a homozygous mutation at DNA response element in the promoter region of specific A2399C causing a Tyr→Ser substititution at residue 628. genes activating transcription [61] . Cardiac metabolic gene This mutation produces a marked decrease in CPT-II expression is activated by PPARa regulation during postactivity in patient fibroblasts [56] . Another mutation has natal development, during short-term starvation and in been reported at C1992T predicting an Arg→Cys substituresponse to exercise training. One marker of PPAR activation at residue 631 which is associated with drastic tion is up-regulated MCAD expression. reduction of CPT-II catalytic activity [57] .
Conversely, pressure-overload hypertrophy results in the de-activation of PPARa with lower fatty acid oxidation sion of a number of nuclear genes involved in mitoexpression, abnormal cardiac lipid homoeostasis and rechondrial OXPHOS including subunits of cytochrome c duced energy production [62] . The negative regulation of oxidase and ATP synthase [66] . PPARa is mediated at several levels with PPAR gene expression being reduced during ventricular overload (in mice). In addition, PPAR activity is altered at the post-6. Animal models of defective fatty acid metabolism transcriptional level via the extracellular signal-regulated and cardiac failure MAP kinase pathway. Ventricular overload therefore results in hypertrophied myocytes with intracellular fat A number of animal models, utilizing some of the accumulation (in response to oleate loading). At this time, molecular findings described in the previous section have the role of PPAR in the activation of the fetal gene been informative in our understanding of the initiation, program occurring during hypertrophy and cardiac failure severity and progression of the cardiac phenotypes associhas not yet been fully delineated.
ated with specific disturbances in fatty acid metabolism. There is also evidence that the PPAR interacting coMice lacking PPARa have a cardiac phenotype of inactivators affect gene regulation by modulation of the creased myocyte lipid accumulation [67] . Mice lacking chromatin structure surrounding the DNA (by changing the MTP a and b subunits alleles show necrosis and acute extent of acetylation of histone residues). degradation of the cardiac myocytes. They also accumulate Recently, it has been shown that PPAR plays a pivotal long-chain fatty acid metabolites, have low birth weight role in mediating the effect of hypoxia on mitochondrial and develop neonatal hypoglycemia with sudden death fatty acid oxidation in cardiac myocytes resulting in between 6 and 36 h after birth [68] . diminished CPT-I b mRNA levels. This is accomplished
To test the hypothesis that disturbance in myocardial via PPAR transcriptional regulation (due to reduced bindfatty acid uptake and utilization leads to the accumulation ing of PPARa) and its obligate partner, retinoid X receptor of cardiotoxic lipid species, and to establish a mouse a (RXRa) to a DNA response element residing within the model of metabolic cardiomyopathy, transgenic mouse CPT-I b promoter [63] . Immunoblot analysis has shown lines that overexpress long-chain acyl-CoA synthetase in that during hypoxia, nuclear and cytoplasmic levels of the heart were generated. These mice demonstrate cardiacRXRa are reduced whereas there is no change in PPAR restricted expression of the transgene and marked cardiac levels.
myocyte triglyceride accumulation. Lipid accumulation was associated with initial cardiac hypertrophy, followed 5.6. Peroxisome proliferator-activated receptor gamma by the development of left-ventricular dysfunction and co-activator (PGC-1) premature death [69] . The role of RXRa in cardiac failure has been further PGC-1 has been identified as a regulator of mitochonprobed in the transgenic mouse as well. RXRa null mutant drial respiratory function in tissues specialized for thermice display ocular and cardiac malformations, liver mogenesis, e.g., brown adipose tissue and skeletal muscle developmental delay, and die from cardiac failure around [64] . PGC-1 gene expression is induced in the mouse heart embryonic day (E) 14.5. To dissect the molecular basis of after birth and in response to short-term fasting, conditions the RXRa-associated cardiomyopathy, subtractive hybridiknown to increase cardiac mitochondrial energy productzation experiments to identify putative downstream target ion.
genes that were selectively lacking in the mutant embryos, Expression of PGC-1 in cardiac myocytes has been showed 50% of the subtracted clones (61 / 115) encoded reported to induce nuclear and mitochondrial gene expresproteins that were involved in fatty acid metabolism and sion involved in multiple mitochondrial energy-transducelectron transport, suggesting an energy deficiency in the tion production pathways, increased mitochondrial number, null RXRa embryos. ATP content and MCAD mRNA and increased respiration. Cardiac-specific overexpression were lower in RXRa mutant hearts compared to wild-type of PGC-1 in transgenic mice resulted in uncontrolled mice. These findings suggest that defects in intermediary mitochondrial proliferation in cardiac myocytes leading to metabolism may be a causative factor of the RXRa 2/ 2 loss of sarcomeric structure and dilated cardiomyopathy.
phenotype, an embryonic form of DCM [70] . These results identify PGC-1 as a critical regulatory molecule in controlling mitochondrial number and function in response to energy demands [65] .
PGC-1 also has been implicated in both the increased 7. Advances in diagnostics and treatment of fatty expression of mitochondrial transcription factor A acid / cardiac disease (mtTFA), which is involved in control of both mitochondrial DNA transcription and replication, and levels of At the outset, a number of treatment recommendations the NRF-1 transcription factor which mediates the exprescan be suggested from the foregoing discussion. It is critical that information concerning the site of defect
